Friday, April 06, 2018 1:35:30 PM
Any idea how Acadia's presentation was received at the annual Needham Healthcare Conference?
"ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018, at 11:30 a.m. Eastern Time in New York City."
"ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018, at 11:30 a.m. Eastern Time in New York City."
Recent ACAD News
- Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career • Business Wire • 04/30/2026 08:05:00 PM
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences • Business Wire • 04/28/2026 08:05:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/28/2026 07:53:50 PM
- Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting • Business Wire • 04/17/2026 01:05:00 PM
- Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 • Business Wire • 04/15/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 11:57:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 11:55:40 PM
- Acadia launches powder version of Rett syndrome treatment in the U.S. • IH Market News • 04/07/2026 01:43:12 PM
- Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome • Business Wire • 04/07/2026 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:00:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:00:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:00:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 10:01:17 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 10:00:14 PM
- Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum • Business Wire • 03/12/2026 08:05:00 PM
- Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors • Business Wire • 03/03/2026 09:05:00 PM
- Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome • Business Wire • 03/02/2026 09:05:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 02/26/2026 11:59:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 09:20:21 PM
- Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview • Business Wire • 02/25/2026 09:05:00 PM
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences • Business Wire • 02/23/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/10/2026 11:00:04 PM
- Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 • Business Wire • 02/04/2026 09:05:00 PM
